5,258 results match your criteria Hairy Cell Leukemia


Comparison of methodologies for the detection of mutations in bone marrow trephine specimens.

J Clin Pathol 2019 Mar 14. Epub 2019 Mar 14.

Division of Cellular and Molecular Pathology, Addenbrooke's Hospital, Cambridge, UK.

Aims: V600E detection assists in the diagnosis of hairy cell leukaemia (HCL); however, testing practices vary. We evaluated the clinical utility of 5 mutation testing strategies for use on bone marrow trephines (BMT).

Methods: 11 HCL, 5 HCL 'mimic', 2 treated HCL and 10 normal BMT specimens were tested for mutant comparing Sanger sequencing, pyrosequencing, amplicon-based next generation sequencing (NGS), automated (Idylla) PCR and immunohistochemistry (IHC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jclinpath-2019-205734DOI Listing

Hairy cell leukemia coexistent with chronic lymphocytic leukemia.

Blood 2019 Mar;133(11):1264

National Institutes of Health Clinical Center.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-12-885145DOI Listing

Decalcification can cause the failure of BRAF molecular analyses and anti-BRAFV600E VE1 immunohistochemistry.

Pathol Int 2019 Mar 7. Epub 2019 Mar 7.

CHRU Brest, Department of Pathology, Brest, F-29220, France.

BRAF mutation detection is worthwhile for the management of patients with some advanced cancers. The tumor samples are sometimes difficult to analyze using DNA-based molecular methods because of poor tumor DNA quality or quantity. Anti-BRAFV600E VE1 immunohistochemistry (IHC) has been proposed as a valuable ancillary tool to analyze some "molecularly challenging" tumor samples. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pin.12784DOI Listing
March 2019
1 Read

Hairy cell leukaemia mimicking multiple myeloma.

Lancet Oncol 2019 Mar;20(3):e187

Institute of Hematology and Center for Hemato-Oncology Research (C.R.E.O.), University and Hospital of Perugia, Perugia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30609-0DOI Listing
March 2019
1 Read

No Loose Ends: A Review of the Pharmacotherapy of Hairy Cell and Hairy Cell Leukemia Variant.

Ann Pharmacother 2019 Mar 6:1060028019836775. Epub 2019 Mar 6.

1 Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Objective: To review the literature for the treatment of classical and variant hairy cell leukemia (HCL, HCLv), evaluating efficacy, safety, and supportive care involved in the use of purine analogues (PAs), interferon, BRAF inhibitors, monoclonal antibodies, Bruton's tyrosine kinase inhibitors, and new immunotoxin, moxetumomab pasudotox-tdfk (MPT). An electronic literature search of PubMed (January 1958 to January 2019) was conducted in PubMed using the MESH terms hairy cell leukemia, hairy cell leukemia variant, cladribine, pentostatin, rituximab, interferon, vemurafenib, moxetumomab pasudotox.

Study Selection And Data Extraction: Studies written in the English language were considered for this article. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1060028019836775
Publisher Site
http://dx.doi.org/10.1177/1060028019836775DOI Listing
March 2019
2 Reads

Current role of interferon in hairy cell leukemia therapy: a timely decision.

Hematol Transfus Cell Ther 2019 Jan-Mar;41(1):88-90. Epub 2018 Jun 11.

Instituto do Câncer do Estado de São Paulo (ICESP), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, SP, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.htct.2018.04.004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371201PMC

BRAF in the cross-hairs.

Expert Rev Hematol 2019 Feb 20:1-11. Epub 2019 Feb 20.

a Leukemia Service , Memorial Sloan Kettering Cancer Center , New York , NY , USA.

Introduction: Hairy cell leukemia (HCL) is a rare, chronic B-cell lymphoproliferative disorder characterized by distinctive morphologic features and an indolent clinical course. The discovery of a recurrent activating mutation in BRAF (BRAF V600E) as a disease-defining genetic event in HCL has substantial diagnostic and therapeutic implications. Areas covered: Herein the authors review the role of BRAF V600E and RAF-MEK-ERK signaling in the pathogenesis of HCL, anecdotal clinical reports of BRAF inhibitor monotherapy in management of relapsed or refractory HCL, larger phase 2 trials investigating efficacy of BRAF inhibitor therapy for HCL, adverse effects commonly associated with BRAF inhibitor therapy, including cutaneous toxicity, and mechanisms of therapeutic resistance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2019.1583553DOI Listing
February 2019
1 Read

Genome-wide promoter methylation of hairy cell leukemia.

Blood Adv 2019 Feb;3(3):384-396

Cancer Sciences Unit, Cancer Research UK and NIHR Experimental Cancer Medicine Centres, University of Southampton, Southampton, United Kingdom.

Classic hairy cell leukemia (HCL) is a tumor of mature clonal B cells with unique genetic, morphologic, and phenotypic features. DNA methylation profiling has provided a new tier of investigation to gain insight into the origin and behavior of B-cell malignancies; however, the methylation profile of HCL has not been specifically investigated. DNA methylation profiling was analyzed with the Infinium HumanMethylation27 array in 41 mature B-cell tumors, including 11 HCL, 7 splenic marginal zone lymphomas (SMZLs), and chronic lymphocytic leukemia with an unmutated (n = 7) or mutated (n = 6) immunoglobulin gene heavy chain variable (IGHV) region or using IGHV3-21 (n = 10). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/bloodadvances.2018024059DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373742PMC
February 2019
2 Reads

Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia.

Br J Haematol 2019 Jan 31. Epub 2019 Jan 31.

Division of Molecular Genetic Epidemiology, German Cancer Research Centre (DKFZ), Heidelberg, Germany.

Improvement of survival in lymphocytic leukaemia has been accompanied by the occurrence of second primary cancer (SPCs). Based on Swedish Family Cancer Database, we applied bi-directional analyses in which relative risks (RRs) were calculated for any SPCs in patients with chronic lymphocytic leukaemia (CLL), acute lymphoblastic leukaemia (ALL) and hairy cell leukaemia (HCL) and the risks of these leukaemias as SPCs. After CLL, RRs were significant for 20 SPCs, and high for skin squamous cell cancer (24·58 for in situ and 7·63 for invasive), Merkel cell carcinoma (14·36), Hodgkin lymphoma (7·16) and Kaposi sarcoma (6·76). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15777DOI Listing
January 2019
2 Reads

Hairy cell leukemia presenting with Ecthyma Gangrenosum- a case report.

BMC Infect Dis 2019 Jan 25;19(1):85. Epub 2019 Jan 25.

Department of Internal Medicine, St Antonius Hospital, Nieuwegein/ Utrecht, Koekoekslaan 1, 3435, CM, Nieuwegein, The Netherlands.

Background: Ecthyma gangrenosum is a cutaneous infectious usually associated with P. aeruginosa. It usually develops In patients with an underlying immunodeficiency. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12879-018-3644-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346580PMC
January 2019
1 Read

BRAF V600E Mutation in Multiple Primary Malignancies: A Hairy Affair.

Cureus 2018 Nov 16;10(11):e3600. Epub 2018 Nov 16.

Hematology & Oncology, Allegheny Health Network, Pittsburgh, USA.

As the number of cancer survivors grows, so does the number of co-occurring primary malignancies and secondary malignancies. In rare cases, single driver mutations can be responsible for concomitant primary malignancies. By understanding the mechanisms that drive multiple primary malignancies (MPM), clinicians are capable of targeting molecular pathways that drive oncogenesis resulting in the successful treatment of many malignancies while also reducing the side effects of conventional chemotherapy. Read More

View Article

Download full-text PDF

Source
https://www.cureus.com/articles/15903-braf-v600e-mutation-in
Publisher Site
http://dx.doi.org/10.7759/cureus.3600DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6338405PMC
November 2018
10 Reads

Disseminated Mucormycosis with Positive Galactomannan.

Case Rep Infect Dis 2018 24;2018:4294013. Epub 2018 Dec 24.

Division of Infectious Diseases, Warren Alpert Medical School of Brown University, Providence, USA.

We describe a case of disseminated mucormycosis () diagnosed on autopsy, in a man who had been working in construction with undiagnosed neutropenia from hairy-cell leukemia, which is rarely associated with invasive mold infections. Galactomannan values in both blood and bronchoalveolar lavage were strongly positive. There is an unmet need for accurate noninvasive fungal diagnostic tests. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/4294013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323503PMC
December 2018
1 Read

Refining the Limits of Borderline Lymphoproliferative Disorders.

Cytometry B Clin Cytom 2018 Dec 28. Epub 2018 Dec 28.

Flow Cytometry Unit, Hematology Laboratory, ICO-Hospital Germans Trias i Pujol, Institut de Recerca Josep Carreras, Universitat Autònoma de Barcelona, Badalona, Spain.

Background: The concept of borderline lymphoproliferative disorder (LPD) has not been clearly defined.

Methods: This study aimed to classify patients with leukemic LPD (n = 597, excluding hairy cell leukemia, mantle cell lymphomas, and CD10-positive LPDs) into CLL or non-CLL applying three diagnostic strategies (the D'Arena and CLLflow scores and CD43 expression) and to better characterize unclassified patients.

Results: Patients with concurring CLL-like (n = 441) or non-CLL like (n = 99) results with the three diagnostic strategies were determined to have CLL and non-CLL, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cyto.b.21760DOI Listing
December 2018
1 Read

CD200 Expression in Diagnostic and Prognostic Assessment of Mature B Cell Lymphophoproliferative Neoplasms

Asian Pac J Cancer Prev 2018 Dec 25;19(12):3383-3392. Epub 2018 Dec 25.

Clinical Pathology Department, Faulty of Medicine, Cairo University, Egypt. Email:

Background: Multiparameter flow cytometry is a useful tool for diagnostic evaluation of mature B-cell neoplasms (MBN). Recently, it has been shown that assessment of CD200 expression may improve the distinction between chronic lymphocytic leukemia (CLL; CD200 positive) and mantle cell lymphoma (MCL; CD200 negative), but any potential as a prognostic marker for CLL remains to be established. Materials and methods: This cross sectional study was conducted on sixty-seven patients newly diagnosed as having mature B-cell lymphoproliferative disorders Levels of CD 200 in lymphoma cells were assessed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.31557/APJCP.2018.19.12.3383DOI Listing
December 2018
3 Reads
1.500 Impact Factor

Overexpression of Hes1 is involved in sensitization of K562 cells to Imatinib.

J Cell Biochem 2018 Dec 11. Epub 2018 Dec 11.

Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.

Tyrosine kinase inhibitor (TKI)-based therapy has created promising results among much chronic myeloid leukemia (CML) patients. Imatinib as a relatively specific inhibitor of Bcr-Abl is at present one of the undisputed therapeutic agent for newlydiagnosed patients with CML. However, the occurrence of imatinib-resistance enlightens the urgent need to identify other therapeutic agents against CML. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/jcb.28296
Publisher Site
http://dx.doi.org/10.1002/jcb.28296DOI Listing
December 2018
5 Reads

Concurrent Hairy Cell Leukemia and Metastatic Merkel Cell Carcinoma.

Case Rep Oncol Med 2018 14;2018:1736854. Epub 2018 Nov 14.

Specialist Care Australia, Launceston, Tasmania, Australia.

Hairy cell leukemia (HCL) and Merkel cell carcinoma (MCC) are two rare malignancies with distinct cells of origin. HCL is a lymphoid malignancy of mature B cells, and MCC derives from neuroendocrine cell origin. HCL has a favorable prognosis with most patients achieving long-term remission and potential cure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/1736854DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6261234PMC
November 2018
14 Reads

Synchronous follicular non-Hodgkin's lymphoma and hairy cell leukaemia: a case report.

Ann Hematol 2018 Dec 4. Epub 2018 Dec 4.

Department of Haematology, St. Vincent's University Hospital, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-018-3573-5DOI Listing
December 2018
4 Reads

Cutaneous adverse events associated with purine analogs in the treatment of hairy cell leukemia.

Int J Dermatol 2018 Nov 27. Epub 2018 Nov 27.

Division of Dermatology, Department of Internal Medicine, Ohio State University Wexner Medical Center, Columbus, OH, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.14320DOI Listing
November 2018
3 Reads

Novel therapeutics in the treatment of hairy cell leukemia variant.

Leuk Res 2018 Dec 5;75:58-60. Epub 2018 Nov 5.

University of Missouri, 1 Hospital Dr, McHaney Hall, Columbia, MO 65212, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2018.11.002DOI Listing
December 2018
2 Reads

Cortactin expression in non-Hodgkin B-cell lymphomas: a new marker for the differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma.

Hum Pathol 2018 Nov 17. Epub 2018 Nov 17.

General Pathology & Cytopathology Unit, Department of Medicine-DIMED, University of Padova, Padova, Italy.

Cortactin is a cytoskeletal-remodeling adaptor protein, playing an oncogenic role in solid tumors. Little is known on Cortactin expression in non-Hodgkin B-cell lymphomas (B-NHL). The present study aimed to characterize Cortactin expression in B-NHL and to assess its role in the differential diagnosis of such entities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2018.10.038DOI Listing
November 2018
7 Reads
2.769 Impact Factor

T-Cell Large Granular Lymphocytic Leukemia - Case Reports.

Acta Clin Croat 2018 Jun;57(2):362-365

Department of Hematology, Sestre milosrdnice University Hospital Centre, Zagreb, Croatia.

T-cell large granular lymphocytic leukemia (T-LGLL) is an uncommon but probably underdiagnosed disease caused by clonal proliferation of large granular lymphocytes. Diagnosis is typically based on the high number of morphologically characteristic lymphoid cells and finding of an abnormal immunophenotype by flow cytometry. Because of its relatively indolent clinical behavior, observation is often an appropriate therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.20471/acc.2018.57.02.18DOI Listing
June 2018
3 Reads

Hairy Cell Leukemia: Retrospective Analysis of Demographic Data and Outcome of 203 Patients from 12 Medical Centers in Israel.

Anticancer Res 2018 Nov;38(11):6423-6429

The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel

Background/aim: In this retrospective study, we summarized the national Israeli experience with hairy cell leukemia (HCL) in a large cohort of patients with a long follow-up.

Patients And Methods: Demographic data, and relevant laboratory and clinical parameters were analyzed, emphasizing the outcome after first-line treatment with cladribine.

Results: Data on 203 patients was collected from 12 medical centers during 1985-2015. Read More

View Article

Download full-text PDF

Source
http://ar.iiarjournals.org/lookup/doi/10.21873/anticanres.13
Publisher Site
http://dx.doi.org/10.21873/anticanres.13003DOI Listing
November 2018
6 Reads

Moxetumomab Pasudotox: First Global Approval.

Authors:
Sohita Dhillon

Drugs 2018 Nov;78(16):1763-1767

Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.

Moxetumomab pasudotox-tdfk (LUMOXITI™), an anti CD22 recombinant immunotoxin, has been developed by MedImmune and its parent company AstraZeneca for the treatment of hairy cell leukaemia. The product, discovered at the National Cancer Institute, is an optimised version of immunotoxin CAT-3888. Moxetumomab pasudotox is composed of the Fv fragment of an anti-CD22 monoclonal antibody fused to a 38 kDa fragment of Pseudomonas exotoxin A, PE38. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-018-1000-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323103PMC
November 2018
2 Reads

New Hairy Cell Leukemia Therapy.

Authors:
Rebecca Voelker

JAMA 2018 Oct;320(15):1528

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2018.15070DOI Listing
October 2018
1 Read

Secondary malignancies after treatment with single-agent vemurafenib in two patients with refractory hairy cell leukemia.

Leuk Lymphoma 2018 Oct 15:1-3. Epub 2018 Oct 15.

a Division of Hematology-Oncology , Scripps Clinic , La Jolla , CA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1519809DOI Listing
October 2018
3 Reads

mutation in hairy cell leukemia: A single-center experience.

Indian J Pathol Microbiol 2018 Oct-Dec;61(4):532-536

Molecular Division, Tata Memorial Centre, Hematopathology Laboratory, Mumbai, Maharashtra, India.

Background: BRAFV600E mutation has been reported as a unique genetic lesion of hairy cell leukemia (HCL), a subset of which lacks this lesion and shows adverse outcomes.

Aims: To determine the prevalence of BRAFV600E in HCL from our center and derive clinicopathological correlation, if any.

Materials And Methods: A 9-year retrospective analysis of 46 consecutive cases of HCL diagnosed on morphology and immunophenotyping was done. Read More

View Article

Download full-text PDF

Source
http://www.ijpmonline.org/text.asp?2018/61/4/532/242988
Publisher Site
http://dx.doi.org/10.4103/IJPM.IJPM_484_16DOI Listing
February 2019
18 Reads

Hairy Cell Leukemia Treatment Approved.

Authors:

Cancer Discov 2018 Nov 27;8(11):OF1. Epub 2018 Sep 27.

The FDA approved moxetumomab pasudotox-tdfk, a CD22-directed recombinant immunotoxin, for patients with relapsed/refractory hairy cell leukemia who have not responded to at least two prior treatments, including a purine nucleoside analogue. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2159-8290.CD-NB2018-126DOI Listing
November 2018
1 Read

Geographic Hematology: Some Observations in Mexico.

Acta Haematol 2018 18;140(2):114-120. Epub 2018 Sep 18.

Centro de Haematología y Medicina Interna de Puebla, Clínica Ruiz, Puebla, Mexico.

In 1963 Jean Bernard introduced the concept of "geographic hematology" and distinguished 2 branches, i.e., "ethnic hematology," which deals with differences between populations, and "environmental hematology," which considers factors such as food habits, infections, and others. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000491989DOI Listing
September 2018
2 Reads

Hairy cell leukemia in a child?!

Blood 2018 Sep;132(11):1216

University Medical Center Utrecht.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-06-857938DOI Listing
September 2018
2 Reads

Case 28-2018: A 39-Year-Old Man with Epistaxis, Pain and Erythema of the Forearm, and Pancytopenia.

N Engl J Med 2018 Sep;379(11):1072-1081

From the Departments of Medicine (C.A.I., R.W.T.), Radiology (F.J.S.), and Pathology (B.J.S.), Massachusetts General Hospital, and the Departments of Medicine (C.A.I., R.W.T.), Radiology (F.J.S.), and Pathology (B.J.S.), Harvard Medical School - both in Boston.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMcpc1807498DOI Listing
September 2018
18 Reads

Antibiotic exposure is associated with cutaneous adverse events in hairy cell leukemia patients treated with purine analogs.

J Am Acad Dermatol 2018 Sep 8. Epub 2018 Sep 8.

Division of Dermatology, Department of Internal Medicine, Ohio State University Wexner Medical Center, Columbus, Ohio.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2018.07.066DOI Listing
September 2018
2 Reads
4.450 Impact Factor

Atypical presentation of hairy cell leukemia: Significance of CD200 on flow cytometry.

J Cancer Res Ther 2018 Jul-Sep;14(5):1130-1134

Department of Hematology, SGPGI, Lucknow, Uttar Pradesh, India.

Hairy cell leukemia (HCL) is a rare, low-grade mature B-cell neoplasm with a characteristic clinical, morphological, immunophenotypic, and more recently described molecular (BRAF p.V600E mutation) profile. It typically affects middle-aged to elderly male who present with pancytopenia and massive splenomegaly. Read More

View Article

Download full-text PDF

Source
http://www.cancerjournal.net/text.asp?2018/14/5/1130/188432
Publisher Site
http://dx.doi.org/10.4103/0973-1482.188432DOI Listing
October 2018
18 Reads

Image Gallery: Hairy-cell leukaemia presenting with Sweet syndrome.

Br J Dermatol 2019 Jan;180(1):e3

Department of Dermatology, University of Rochester Medical Center, Rochester, NY, U.S.A.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.17157DOI Listing
January 2019
2 Reads

Aplastic anemia.

Vnitr Lek 2018 ;64(5):501-507

Aplastic anemia - bone marrow failure (AA) is defined as pancytopenia with hypocellular bone marrow without signs of marrow fibrosis or of presence of abnormal cells. Recent studies showed that most of AA cases might be mediated by immune mechanisms. Toxic agent leads to expression of neoantigens or cryptic antigens on the surface of pluripotent hematopoietic stem cells with subsequent activation of immune effector cells and induction of stem cell apoptosis. Read More

View Article

Download full-text PDF

Source
January 2018
15 Reads

Targeting Mutations in High-Grade Neuroendocrine Carcinoma of the Colon.

J Natl Compr Canc Netw 2018 09;16(9):1035-1040

Division of Medical Oncology, Department of Internal Medicine

Mutations in the RAS/RAF/MEK/ERK pathway leading to constitutive activation and uncontrolled cellular growth have been identified in various human malignancies, making this pathway a target for potential therapeutics. The activating mutation is one well-characterized oncogenic mutation that has been described and targeted with clinical success in various malignancies, including melanoma and hairy cell leukemia. Although -directed treatments have yielded clinical benefit in a subset of tumor types, such as melanoma, thyroid cancer, and lung cancer, BRAF inhibition fails to confer a clinical benefit in colon cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2018.7043DOI Listing
September 2018
6 Reads

Biclonal IGHV-4-34 hairy cell leukemia variant and CLL - successful treatment with ibrutinib and venetoclax.

Am J Hematol 2018 Dec 2;93(12):1568-1569. Epub 2018 Oct 2.

Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/ajh.25264
Publisher Site
http://dx.doi.org/10.1002/ajh.25264DOI Listing
December 2018
6 Reads

Skeletal involvement of hairy cell leukemia.

Clin Case Rep 2018 Aug 2;6(8):1651-1652. Epub 2018 Jul 2.

Service d'Hématologie Clinique Centre Hospitalier Universitaire Hôpital Robert Debré Reims France.

Hairy cell leukemia (HCL) is a rare B-cell lymphoproliferative disorder. Skeletal involvement is an unusual manifestation of HCL, complicating the course of the disease in approximately 3% of patients. We describe a case of skull involvement by HCL, a localization rarely reported in the literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccr3.1635DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6099005PMC
August 2018
8 Reads

[Research Progress on Diagnosis and Treatment of B Cell Chronic Lymphoproliferative Disease--Review].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2018 Aug;26(4):1220-1224

Department of Hematology, Tianjin Medical University Cancer Hospital; National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy; Tianjin 300060, China.E-mail:

The 2016 world health organization (WHO) classification of B cell chronic lymphoproliferative disease (B-CLPD) includes chronic lymphocytic leukemia (CLL), B prolymphocytic leukemia, (B-PLL), hairy cell leukemia (HCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), mantle cell lymphoma (MCL), Waldenstrom macroglobulinemia (LPL/WM). All the above-mentioned diseases are partially similar in cell morphology, immunophenotype and molecular genetics, but significantly different in treatment and prognosis. Currently, many new drugs targeted at cell cycle and apoptosis pathway, such as proteasome inhibitor immune modulators and histone deacetylase inhibitors, have achieved encouraging results in B-CLPD, which bring new hope for patients with B-CLPD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7534/j.issn.1009-2137.2018.04.046DOI Listing
August 2018
3 Reads

Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?

Mult Scler J Exp Transl Clin 2018 Apr-Jun;4(2):2055217318783767. Epub 2018 Jun 26.

BartsMS, Blizard Institute, Queen Mary University of London, United Kingdom.

Background: A considerable number of people with multiple sclerosis (pwMS) live in low- and middle-income countries (LMIC), where lack of resource adversely affects access to effective disease-modifying treatment.

Objective: The objective of this commentary is to propose a useful cost-effective disease-modifying treatment option for pwMS in LMIC with potential high efficacy and high convenience to the pwMS and treating physician.: We propose using generic 2-chloro-2'-deoxyadenosine (cladribine), a small molecule licensed for treatment of people with hairy cell leukaemia, as a solution of this significant equity imbalance. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2055217318783767DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6077935PMC
June 2018
11 Reads

Clinicopathological features of splenic tumours of lymphoid tissue.

Pathol Res Pract 2018 Dec 27;214(12):1952-1958. Epub 2018 Jul 27.

Department of Pathology, Xinjiang Medical University Cancer Hospital, New City District Suzhou Street No. 789, Urumqi, 830000, China.

Background: To study the effects of splenectomy on treatment and diagnosis of tumours of lymphoid tissue of the spleen.

Methods: Fifty-three cases were reviewed from Peking University People's Hospital from 2002 to 2017. According to WHO classification of tumours of haematopoietic and lymphoid tissues (2008) and classification updated (2016), the cases were studied by microscopy, immunohistochemistry and in situ hybridization, combined with the bone marrow biopsy and clinical examination. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prp.2018.07.021DOI Listing
December 2018
4 Reads

A BRAF-mutated case of hairy cell leukaemia lacking Annexin-A1 expression.

Br J Haematol 2018 Dec 24;183(5):702. Epub 2018 Jul 24.

Institute of Haematology and Centre of Haemato-Oncology Research (CREO), University and Hospital of Perugia, Perugia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15502DOI Listing
December 2018
2 Reads

Identification of the BRAF V600E mutation in Japanese patients with hairy cell leukemia and related diseases using a quenching probe method.

Int J Hematol 2018 Oct 24;108(4):416-422. Epub 2018 Jul 24.

Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, 849-8501, Japan.

Hairy cell leukemia (HCL) is a rare B-cell lymphoid malignancy that is difficult to distinguish from other morphological variants. The frequency of HCL has not been determined accurately in Japan. Recent studies revealed that the BRAF V600E mutation is the causal genetic event in HCL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12185-018-2506-3DOI Listing
October 2018
4 Reads

[Clinical analysis of 24 patients of hairy cell leukemia treated by cladribine].

Zhonghua Xue Ye Xue Za Zhi 2018 Jun;39(6):491-495

Institute of Hematology & Blood Disease Hospital, CAMS & PUMC, State Key Laboratory of Experimental Hematology, Tianjin 300020, China.

To investigate the curative effect of hairy cell leukemia by clatabine. The clinical data of 24 patients with hairy cell leukemia treated by cladribine from November 2006 to October 2017 were analyzed retrospectively, then the curative effect and adverse drug reaction were analyzed. ① A total of 24 patients including 22 male and 2 female, and the median age was 49. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.06.011DOI Listing
June 2018
4 Reads

Atypical "hairy cell-like" presentation of leukemic mantle cell lymphoma.

Clin Chem Lab Med 2018 Dec;57(2):e34-e36

Department of Internal Medicine 1, Hospital of the Brothers of St. John of God, Graz, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1515/cclm-2018-0633DOI Listing
December 2018
3 Reads

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.

Leukemia 2018 Aug 20;32(8):1768-1777. Epub 2018 Jul 20.

Developmental Therapeutics Consortium, Chicago, IL, USA.

This is a pivotal, multicenter, open-label study of moxetumomab pasudotox, a recombinant CD22-targeting immunotoxin, in hairy cell leukemia (HCL), a rare B cell malignancy with high CD22 expression. The study enrolled patients with relapsed/refractory HCL who had ≥2 prior systemic therapies, including ≥1 purine nucleoside analog. Patients received moxetumomab pasudotox 40 µg/kg intravenously on days 1, 3, and 5 every 28 days for ≤6 cycles. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41375-018-0210-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087717PMC
August 2018
50 Reads
10.431 Impact Factor

New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes.

Oncotarget 2018 Jun 22;9(48):28866-28876. Epub 2018 Jun 22.

Normandie Univ, INSERM U1245, Université de Caen, Caen, France.

Classical hairy cell leukemia (HCL-c) is a rare lymphoid neoplasm. mutation, detected in more than 80% of the cases, is described as a driver mutation, but additional genetic abnormalities appear to be necessary for the disease progression. For cases of HCL-c harboring a wild-type gene, the differential diagnosis of the variant form of HCL (HCL-v) or splenic diffuse red pulp lymphoma (SDRPL) is complex. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.25601DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034755PMC
June 2018
7 Reads

Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells.

Cell Cycle 2018 3;17(8):985-996. Epub 2018 Jul 3.

b School of Medicine , University of Colorado Anschutz Medical Campus , Aurora , CO , USA.

Cladribine (2CdA), a synthetic purine analog interfering with DNA synthesis, is a medication used to treat hairy cell leukemia (HCL) and B-cell chronic lymphocytic leukemia. Entinostat, a selective class I histone deacetylase (HDAC) inhibitor, shows antitumor activity in various human cancers, including hematological malignancies. The therapeutic potential of cladribine and entinostat against multiple myeloma (MM) remains unclear. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/15384101.2018.1464849DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197031PMC
July 2018
3 Reads